Princeton Global Asset Management LLC Purchases 123 Shares of Eli Lilly and Company $LLY

Princeton Global Asset Management LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 26.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 585 shares of the company’s stock after acquiring an additional 123 shares during the quarter. Princeton Global Asset Management LLC’s holdings in Eli Lilly and Company were worth $456,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LLY. Precedent Wealth Partners LLC increased its stake in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares during the last quarter. Capital Advisors Inc. OK lifted its stake in shares of Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the last quarter. Family CFO Inc purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $54,000. Duquesne Family Office LLC boosted its holdings in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares during the period. Finally, Corient IA LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $570,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, Director Jamere Jackson bought 200 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 1.9%

Shares of LLY opened at $803.53 on Monday. The firm has a market capitalization of $760.51 billion, a price-to-earnings ratio of 52.52, a PEG ratio of 1.15 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The company has a 50-day moving average of $753.09 and a 200 day moving average of $765.70.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 earnings per share. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Guggenheim reaffirmed a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. UBS Group cut their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Leerink Partners reissued a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $939.12.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.